cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Vor Biopharma Inc
5 own
4 watching
Current Price
$2.04
$0.07
(3.55%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
118.99M
52-Week High
52-Week High
5.70000
52-Week Low
52-Week Low
1.62000
Average Volume
Average Volume
0.18M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization118.99M
icon52-Week High5.70000
icon52-Week Low1.62000
iconAverage Volume0.18M
iconDividend Yield--
iconP/E Ratio--
What does the Vor Biopharma Inc do?
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Vor Biopharma Inc make?
News & Events about Vor Biopharma Inc.
Benzinga
10 months ago
Vor Biopharma Inc(NASDAQ: VOR) presented updated data from patients treated in the VBP101 Phase 1/2a study of trem-cel (formerly VOR33) inread more...
Globe Newswire
10 months ago
Patients transplanted with trem-cel achieved primary neutrophil engraftment and high levels of myeloid donor chimerism.Strong investigator enthusiasm and continued robust enrollment; additional data updates expected by year-end 2023.U.S. FDA clears VCAR33ALLO IND.Conference call scheduled for today...
Globe Newswire
1 year ago
SAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO(rezafungin for injection) for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. ...
Globe Newswire
1 year ago
CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: H.C. Wainwright Cell Therapy Virtual ConferenceFireside Chat recording available ...
Globe Newswire
1 year ago
Trem-cel exhibited robust engraftment five months post-transplant through three cycles of MylotargMylotarg treatment enriched CD33-negative donor hematopoiesisSecond patient successfully received trem-cel transplant and achieved neutrophil engraftment and platelet recovery CAMBRIDGE, Mass., Feb. 16...
Frequently Asked Questions
Frequently Asked Questions
What is Vor Biopharma Inc share price today?
plus_minus_icon
Can Indians buy Vor Biopharma Inc shares?
plus_minus_icon
How can I buy Vor Biopharma Inc shares from India?
plus_minus_icon
Can Fractional shares of Vor Biopharma Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Vor Biopharma Inc stocks?
plus_minus_icon
What is today’s traded volume of Vor Biopharma Inc?
plus_minus_icon
What is today’s market capitalisation of Vor Biopharma Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Vor Biopharma Inc?
plus_minus_icon
What percentage is Vor Biopharma Inc down from its 52-Week High?
plus_minus_icon
What percentage is Vor Biopharma Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$2.04
$0.07
(3.55%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00